869294-30-4

Upstream product

• 319-24-4 2-amino-5-fluoro-benzoic acid methyl ester 
• 623-49-4 ethyl cyanoformate 

Downstream Products

• 1241915-89-8 (4-(1H-Pyrazol-3-ylamino)-6-fluoroquinazolin-2-yl)(4-fluorophenyl)-methanone 
• 1241915-88-7 (R,S)-(4-(1H-pyrazol-3-ylamino)-6-fluoroquinazolin-2-yl)(4-fluorophenyl)methanol 
• 1241915-86-5 (4-chloro-6-fluoroquinazolin-2-yl)(4-fluorophenyl)-methanone 
• 1241915-85-4 (6-fluoro-4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone 
• 935758-98-8 6-fluoro-4-oxo-N-[(3-{[2-(1H-1,2,4-triazol-3-ylthio)ethyl]oxy}phenyl)methyl]-3,4-dihydroquinazoline-2-carboxamide 

Relevant academic research and scientific papers

ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.

JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).